

## REFERENCES

- Algren, D.A. Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients. 2010 [cited 2016 Aug 10]. Available from: [http://www.who.int/selection\\_medicines/committees/expert/18/applications/OrralIronChelators.pdf](http://www.who.int/selection_medicines/committees/expert/18/applications/OrralIronChelators.pdf) URL:
- Calvaruso, G., Vitrano A., Maggio, R.D., Lai, E., Colletta, G., Quota, A., Gerardi, C., Rigoli, L.C., Sacco, M., Pitrolo, L., Maggio, A. 2015. Deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial. *American Journal of Hematology*, vol. 90, no. 7, p. 634-638
- Cappellini, M.D., Alan, C., John, P., Ali, T., Viprakasit V. 2014. *TIF – Guidelines for the Management of Transfusion Dependent Thalassemia*. 3<sup>rd</sup> edition. Cyprus: Thalassaemia International Federation
- Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Aqaoqlu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermynen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P., Alberti, D. 2006. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with  $\beta$ -thalassemia. *Blood*, vol. 107, no. 9, p. 3455-3462
- Cassinerio E., Roghi A., Pedrotti P., Brevi F., Zanaboni L., Graziadei G., Pattoneri P., Milazzo A., Cappellini M.D. 2012. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. *Ann Hematol*, vol. 91, no.9, p. 1443-1449
- Galanello, R., Origa, R. 2010. Beta-thalassemia. *Orphanet journal of Rare Diseases*, vol. 5, no. 11
- Ganz T., Nemeth E. 2011. Hepcidin and disorders of iron metabolism. *Annu Rev Med*, vol. 62, p. 347-360
- Gartlehner, G., Hansen, R.A., Nissman, D., Lohr, K.N., Carey, T.S. 2006. *Criteria for distinguishing effectiveness from efficacy trials in systematic reviews*. United States: Agency for Healthcare Research and Quality

- Gomber S., Saxena R., Madan N. 2004. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. *Indian Pediatr*, vol. 41, no. 1, p. 21-27
- Harteveld, C.L., Higgs, D.R. 2010.  $\alpha$ -thalassemia. *Orphanet Journal of Rare Diseases*, vol. 5, no. 13
- Hassan, M.A.M., Tolba, O.A. 2016. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferiasirox and deferoxamine. *Electronic Physician*, vol. 8, issue 5, p. 2425-2431
- Hejazi, S., Safari, O., Arjmand, R., Qorbani, M., Pourrostami, K., Safari, A., Hemmati, A. 2016. Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial. *Int J Pediatr*, vol. 4, no. 6, p. 1959-1965
- Hillman, R.S., Ault, K.A., Loporrier, M., Rinder, H.M. 2011. *Hematology in Clinical Practice*. United States: McGrawHill Inc
- Hoffbrand, A.V., Petit, J.E., Moss, P.A.H. 2005. *Kapita Selekt Hematologi*. 4<sup>th</sup> edition. Jakarta: EGC
- Ismail, Y., Reniarti, L., Hilmento, D. 2010. Perbedaan Kadar Feritin Serum Anak Penyandang Thalassemia Mayor Setelah Pemberian Kelator Besi Deferiprone dan Deferoxamine. *Majalah Kedokteran Indonesia*, vol. 60, no. 11, p. 512-515
- Mishra, A.K., Tiwari A. 2013. Iron Overload in Beta Thalassaemia Major and Intermedia Patients. *MAEDICA*, vol. 8, no. 4, p. 328-332
- Nienhuis, A.W., Nathan, D.G. 2012. Pathophysiology and Clinical Manifestations of the  $\beta$ -Thalassemias. *Cold Spring Harb Perspect Med*, vol. 2, no. 12
- Permono, H.B., Sutaryo, Ugrasena, I.D.G., Windiastuti, E., Abdulsalam, M. 2010. *Buku Ajar Hematologi-Onkologi Anak*. 3<sup>rd</sup> edition. Badan Penerbit IDAI: Indonesia
- Prabhu, R., Prabhu, V., Prabhu, R.S. 2009. Iron Overload in Beta Thalassemia – A Review. *J Biosci Tech*, vol. 1, no. 1, p. 20-31
- Pudjiadi, A.H., Hegar, B., Handryastuti, S., Idris, N.S., Gandaputra, E.P., Harmoniati, E.D. 2009. *Pedoman Pelayanan Medis Ikatan Dokter Anak Indonesia*. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia
- Sastroasmoro S., Ismael, S. 2011. *Dasar – dasar metodologi penelitian klinis*. 4<sup>th</sup> edition. Jakarta: Sagung Seto

- Verissimo, M.P.D.A., Loggetto, S.R., Junior, A.F., Baldanzi, G.R., Hamerschlak, N., Fernandes, J.L., Araujo, A.D.S., Lobo, C.L.D.C., Fertrin, K.Y., Berdoukas, V.A., Galanello, R. 2013. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. *Rev Bras Hematol Hemoter*, vol. 35, no. 6, p. 428-434
- Wang, W., Knovich, M.A., Coffman, L.G., Torti, F.M., Torti, S.V. 2010. Serum Ferritin: Past, Present and Future. *Biochim Biophys Acta*, vol. 1800, no. 8, p. 760-769
- Xia, S., Zhang, S., Huang, L., Jiang, H. 2013. Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Sever Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials. *PLOS ONE*, vol. 8, issue 12 p. 1-9